Brand-Backed ASBM Pushes Back On Biosimilar Reforms

 
• By Dave Wallace

The Alliance for Safe Biologic Medicines urged restraint when considering FDA findings suggesting switching studies may not be as vital to support interchangeability.

Large yellow arrow opposing multiple small white arrows on chalkboard
The ASBM is pushing back against recent FDA moves on biosimilars. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics